🎗️ Melanoma — 2026-W42

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Retrospective multicenter cohort of patients with unresectable stage III/IV melanoma treated with checkpoint blockade, published in J Immunother Cancer. Suggests poliosis as an accessible clinical marker of durable response, though hypothesis-generating and not yet practice-changing.

Multicenter international retrospective cohort of patients aged 75+ with resected stage III-IV melanoma, published in J Immunother Cancer. Suggests adjuvant systemic therapy is associated with better melanoma-specific survival than observation in older patients, informing adjuvant decisions in this under-represented group.

Translational bioinformatics atlas of alternative splicing across immunotherapy cohorts, published in J Immunother Cancer. Identifies candidate splicing events linked to poor immune infiltration and survival in melanoma, but these need further functional and clinical validation before informing ICB decisions.